Proof of concept study, a randomized, controlled, open and prospective period of one year to evaluate the effectiveness of treatment with saxagliptin / dapagliflozin + metformin vs insulin glargine + metformin in patients with Autoimmune Diabetes of the Adult (LADA) Proof of concept study
Latest Information Update: 30 Apr 2024
At a glance
- Drugs Dapagliflozin (Primary) ; Insulin glargine (Primary) ; Metformin (Primary) ; Saxagliptin (Primary)
- Indications Latent autoimmune diabetes in adults
- Focus Pharmacokinetics; Proof of concept
- Acronyms Proof of concept study on LADA
- 30 Apr 2024 Results compare the efficacy and safety of saxagliptin/dapagliflozin and insulin glargine in people with latent autoimmune diabetes in adults , published in the Diabetes, Obesity and Metabolism
- 23 Aug 2021 Planned End Date changed to 5 Feb 2017.
- 23 Aug 2021 New trial record